Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
暂无分享,去创建一个
Päivi Heikkilä | Carlos Caldas | Arto Mannermaa | Annegien Broeks | Manjeet K Bolla | Heli Nevanlinna | Angela Cox | Javier Benitez | Rainer Fagerholm | Carl Blomqvist | Janet E Olson | Simon S Cross | Vesa Kataja | Primitiva Menéndez | Jolanta Lissowska | Peter Devillee | Fergus J Couch | Elena Provenzano | Frances Daley | Penny Coulson | Jonine Figueroa | Douglas F Easton | Antoinette Hollestelle | William J Howat | Sarah Pinder | Patrycja Gazinska | Louise Jones | S. Cross | J. Olson | F. Couch | M. García-Closas | J. Benítez | A. Cox | D. Easton | A. Hollestelle | A. Broeks | C. Caldas | E. Provenzano | S. Dawson | S. Pinder | P. Pharoah | M. Sherman | D. Visscher | L. Brinton | J. Lissowska | H. Nevanlinna | R. Fagerholm | I. Brock | M. Reed | A. Mannermaa | V. Kosma | V. Kataja | M. Schmidt | M. Bolla | C. Blomqvist | J. I. Pérez | E. Sawyer | J. Figueroa | M. Brook | P. Menéndez | P. Heikkilä | J. Wesseling | C. V. van Deurzen | W. Mesker | F. Daley | F. Blows | H. R. Ali | W. Howat | P. Gazinska | L. Jones | P. Coulson | L. Morris | R. Sironen | Jelle Wesseling | Jose Ignacio Arias Perez | J. Sanders | Leigh‐Anne McDuffus | Mark E Sherman | Marjanka K Schmidt | Paul D Pharoah | Elinor J Sawyer | Carolien H M van Deurzen | Louise Brinton | Joyce Sanders | Leigh‐Anne McDuffus | Fiona M Blows | Mark N Brook | Lorna Morris | Nicola Johnson | Jodi Miller | Reijo Sironen | Daniel Visscher | H Raza Ali | Sarah‐Jane Dawson | Veli‐Matti Kosma | Ian W Brock | Malcolm W Reed | Wilma E Mesker | Caroline M Seyaneve | Montserrat García‐Closas | Jodi L Miller | Peter Devillee | Nicola Johnson | Jodi L. Miller
[1] H. Grabsch,et al. Guidelines and considerations for conducting experiments using tissue microarrays , 2013, Histopathology.
[2] E Provenzano,et al. Astronomical algorithms for automated analysis of tissue protein expression in breast cancer , 2013, British Journal of Cancer.
[3] Valerie Speirs,et al. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example , 2012, Journal of Clinical Pathology.
[4] S. Cross,et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.
[5] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[6] Søren Nielsen,et al. Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains , 2012, Breast Cancer Research and Treatment.
[7] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Andrew H. Beck,et al. Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.
[9] Holger Lange,et al. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens. , 2011, Archives of pathology & laboratory medicine.
[10] Mikael Lundin,et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer , 2011, BMC clinical pathology.
[11] Mark T. W. Ebbert,et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.
[12] N. A. Walton,et al. PathGrid: a service-orientated architecture for microscopy image analysis , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[13] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[14] M. García-Closas,et al. Molecular Pathology in Epidemiologic Studies: A Primer on Key Considerations , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[15] Sean Davis,et al. Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[16] Marilyn M. Bui,et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? , 2010, Journal of pathology informatics.
[17] Margaret Grant,et al. Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience , 2009, Histopathology.
[18] D. Mayr,et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH) , 2009, Virchows Archiv.
[19] William M Gallagher,et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer , 2008, Breast Cancer Research.
[20] L. Goldstein,et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases , 2008, Breast Cancer Research and Treatment.
[21] G. Turashvili,et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis , 2007, BMC Cancer.
[22] D. Rimm,et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.
[23] C. Gomez-Fernandez,et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.
[24] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[25] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[28] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[30] J. Bacus,et al. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. , 1988, American journal of clinical pathology.
[31] W. Onuigbo. Some Pathological Data on 2000 Adenocarcinomas and Squamous Cell Carcinomas of the Lung , 1963, British Journal of Cancer.